You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,809,330


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,809,330
Title:Pyrazolo[1,5-A]pyrimidines for antiviral treatment
Abstract: The invention provides compounds of Formula I or Formula II: ##STR00001## or a pharmaceutically acceptable salt or ester, thereof, as described herein. The compounds and compositions thereof are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.
Inventor(s): Babaoglu; Kerim (Pacifica, CA), Boojamra; Constantine G. (San Francisco, CA), Eisenberg; Eugene J. (San Carlos, CA), Hui; Hon Chung (San Mateo, CA), Mackman; Richard L. (Milbrae, CA), Parrish; Jay P. (Redwood City, CA), Sangi; Michael (Oakland, CA), Saunders; Oliver L. (San Mateo, CA), Siegel; Dustin (Foster City, CA), Sperandio; David (Palo Alto, CA), Yang; Hai (San Mateo, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:14/069,685
Patent Claims:1. A method of treating a Pneumovirinae virus infection in a human in need thereof comprising administering to the human a therapeutically effective amount of a compound of formula: ##STR00774## or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 wherein the Pneumovirinae virus infection is caused by human respiratory syncytial virus.

3. The method of claim 1 further comprising administering a therapeutically effective amount of at least one other therapeutic agent selected from ribavirin, palivizumab, motavizumab, RSV-IGIV, MEDI-557, A-60444, MDT-637, BMS-433771, ALN-RSV0 and ALX-0171, or mixtures thereof.

4. The method of claim 1 wherein the therapeutically effective amount is a daily dose of from 1 mg to 1,000 mg administered in a single dose or multiple doses.

5. The method of claim 4 wherein the therapeutically effective amount is administered orally.

6. The method of claim 5 wherein the therapeutically effective amount is administered in an aqueous solution or suspension.

7. The method of claim 1 wherein the therapeutically effective amount is a daily dose of from 5 mg to 500 mg administered in a single dose or multiple doses.

8. The method of claim 7 wherein the therapeutically effective amount is administered orally.

9. The method of claim 7 wherein the therapeutically effective amount is administered in an aqueous solution or suspension.

10. The method of claim 1 wherein the pharmaceutically acceptable salt is a trifluoroacetic acid salt.

Details for Patent 8,809,330

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Swedish Orphan Biovitrum Ab (publ) SYNAGIS palivizumab For Injection 103770 06/19/1998 ⤷  Try a Trial 2030-06-24
Swedish Orphan Biovitrum Ab (publ) SYNAGIS palivizumab Injection 103770 07/23/2004 ⤷  Try a Trial 2030-06-24
Hoffmann-la Roche Inc. PEGASYS COPEGUS COMBINATION PACK peginterferon alfa-2a and ribavirin 125083 06/04/2004 ⤷  Try a Trial 2030-06-24
Schering Corporation A Subsidiary Of Merck & Co., Inc. PEGINTRON/ REBETOL COMBO PACK peginterferon alfa-2b and ribavirin 125196 06/13/2008 ⤷  Try a Trial 2030-06-24
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.